JAZZJazz Pharmaceuticals plc
$218.41+70% 1Y
$218.41
$127.0052 weeks$261.72
JAZZ in its own filings
JAZZ's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
451
Events found in the filings · across 2,182 filings · the record starts in 2005
- Hard flags
- 1
Hard flags
- Most recent filing
- Oct 9, 2026
Most recent filing · Form 8-K
- Record starts
- Apr 28, 2005
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Change in certifying accountanthistorical
- 2012-02-28
- Delisting notice / listing-rule failurehistorical
- 2012-07-23
- Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares
- 2012-01-18
- Material impairmenthistorical
- 2018-06-29
- SEC comment-letter activity43 occurrences
- 2025-08-08
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 9, 2026On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company” ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.Director or officer change · Form 8-K
- Sep 23, 2026For the purpose of extending the maturity date and repricing the outstanding U.S. dollar term loan B-2 facility incurred on July 19, 2024 (the “Tranche B-2 Dollar Term Loans”), on September 23, 2026, Jazz Financing Lux S.à r.l., a private limited liability company ( société à responsabilité limitée ) incorporated and …Material agreement entered · Form 8-K
- Sep 15, 2026Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences.Regulation FD disclosure · press release
- Aug 31, 2026Closing of Exchangeable Senior Notes Offering On August 31, 2026, Jazz Investments I Limited, a Bermuda exempted company limited by shares (the “Issuer”) and a wholly-owned subsidiary of Jazz Pharmaceuticals plc (the “Company”), completed its previously announced private offering of $1.25 billion aggregate principal …Material agreement entered · Form 8-K
- Aug 25, 2026On August 25, 2026, Jazz Pharmaceuticals plc (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) …Other event · Form 8-K
- Aug 10, 2026On August 10, 2026, Jazz Pharmaceuticals, Inc. (“Parent”), a wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company (“Jazz”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Knight Acquisition Corp., a Delaware corporation and a direct or indirect wholly-owned subsidiary of …Material agreement entered · Form 8-K
- Aug 10, 2026Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio.Regulation FD disclosure · press release
- May 29, 2026On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…